Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, toda...

Alaunos Therapeutics has agreed to raise about $349.95 million through a private placement of stock. It signed a Securities Purchase Agreement to sell 687,789 shares of common stock at $1.4357 per share and 243,063 shares of Series C preferred stock at $1,435.70 per share. The common stock brings in about $987,459, and the preferred stock about $348.97 million. The deal is expected to close on October 14, 2026, subject to customary closing conditions. Fairmount led the placement of Series C non-voting convertible preferred stock. Venrock Healthcare Capital Partners, T. Rowe Price Investment Management, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management, ADAR1 Capital Management and other firms took part.

We just closed an employee tender offer which values ElevenLabs at $22BN, up 2x from our Series D in February. The tender was led by Wellington and T. Rowe Price, and the growth is driven by demand from enterprises to deploy ElevenAgents across sales, support, and operations. In 2022, we raised our first round at a $9 million valuation, which we announced alongside Eleven v1, our first Text to Speech model, and the first model to generate human-level speech. Four years later, as we reach our new valuation, we just released two new state-of-the-art Text to Speech models. Eleven v4 and v4 Turbo are our fastest and most emotive models yet, and are leading independent benchmarks. Alongside models, we have built a full interaction platform for AI. It allows organizations to deploy conversational agents, connected to their knowledge and systems, that interact naturally in any industry, geography, or context. This shift is driving much of our growth, with enterprise now accounting for 55% of our revenue, as businesses adopt ElevenAgents to support their customers and employees. Our technology is now used in daily operations at five of the world’s ten largest tech companies, five of the ten largest insurers, and four of the ten largest telecoms. The round was co-led by Wellington Management and T. Rowe Price, along with participation from Goldman Sachs, GIC, Ontario Teachers'​ Pension Plan, EQT Group, Sapphire Ventures, and BDT & MSD Partners. And grateful for ongoing support from existing investors including Andreessen Horowitz, Alkeon Capital, The D. E. Shaw Group, Disruptive, Evantic Capital, ICONIQ, and Lightspeed. Most of all, this round is for the team that built the last four years. We're just getting started! | 89 comments on LinkedIn